The Molecular Cytogenetics Core was involved in the following projects: 1. Detection of IgH rearrangements in CD138+ purified tumor cells from patients with MGUS or SMM. Collaboration with Dr. O.Landgren (Medical Oncology Branch, CCR, NCI), NCI Protocol #: 10-C-0096, Natural history of monoclonal gammopathy of undetermined significande (MGUS) and smoldering myeloma (SMM). 2. Detection of IgH rearrangements in CD138+ purified tumor cells from patients with multiple myeloma. Collaboration with Dr. O. Landgren (Medical Oncology Branch, CCR, NCI), NCI Protocol: Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study. 3. Comprehensive characterization of a panel of malignant mesothelioma cell lines using array comparative genomic hybridization (aCGH) and spectral karyotyping (SKY) (collaboration with Dr. G. Klorin, Dr. O. Glebov, Dr. E.Rozenblum, Dr. F.Kaye, Dr. R.Walker, Dr. P.Meltzer). 4. Delineation of complex chromosomal rearrangements and identification of IgH translocation partners by FISH mapping in multiple myeloma cell lines, detection and delineation of non-IgH aberrations. Karyotypic characterization by SKY of multiple myeloma cell lines and subclones, hybridoma clones with single human chromosome (collaboration with Dr. W.M.Kuehl). 5. Spectral karyotyping of a set of multiple myeloma cell lines and short term cultures, comparison of FISH and SKY data (collaboration with Dr. M. Kuehl and Dr. A. Protopopov). 6. Immortalization and comprehensive characterization of a human ovarian adenocarcinoma cell line derived from an Ashkenazi Jewish patient (collaboration with Dr. E.Rozenblum). 7. Delineation of chromosomal rearrangements produced in clones of monocytic leukemia cell line U937 by RAG- and I-SceI- induced breaks (collaboration with Dr. P.Aplan).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICBC010930-06
Application #
8763732
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2013
Total Cost
$408,697
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Affer, M; Chesi, M; Chen, W D et al. (2014) Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28:1725-35
Kim, Gina Y; Gabrea, Ana; Demchenko, Yulia N et al. (2014) Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets. Genes Chromosomes Cancer 53:467-74
Klorin, Geula; Rozenblum, Ester; Glebov, Oleg et al. (2013) Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines. Cancer Genet 206:191-205
Roschke, Anna V; Rozenblum, Ester (2013) Multi-layered cancer chromosomal instability phenotype. Front Oncol 3:302
Cheng, Yue; Zhang, Zhenhua; Keenan, Bridget et al. (2010) Efficient repair of DNA double-strand breaks in malignant cells with structural instability. Mutat Res 683:115-22
Roschke, Anna V; Kirsch, Ilan R (2010) Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells. Curr Drug Targets :
Roschke, Anna V; Kirsch, Ilan R (2010) Targeting karyotypic complexity and chromosomal instability of cancer cells. Curr Drug Targets 11:1341-50
Roschke, Anna V; Glebov, Oleg K; Lababidi, Samir et al. (2008) Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin mai Neoplasia 10:1222-30
Gabrea, Ana; Martelli, Maria Luisa; Qi, Ying et al. (2008) Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer 47:573-90